Intravesical therapy with vinorelbine tartrate: Antitumor activity in orthotopic murine cell carcinoma of the bladder

被引:7
作者
Bonfil, RD
Russo, DM
Schmilovich, AJ
GarciaPalazzo, IB
机构
[1] RONTAG LABS,BUENOS AIRES,DF,ARGENTINA
[2] TEMPLE UNIV HOSP & MED SCH,PHILADELPHIA,PA 19140
关键词
vinorelbine; bladder neoplasms; chemotherapy;
D O I
10.1016/S0022-5347(01)64363-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To ascertain intravesical vinorelbine tartrate (VNR) antitumor activity against MB-49, a murine transitional cell carcinoma of the bladder (TCC), in an in vivo setting. Materials and Methods: C57Bl/6J female mice were intravesically implanted with 5 x 10(4) MB-49 cells and treated locally with VNR. Tumor incidence and volume analyses, as well as survival studies were carried out. Results: Tumor incidence was significantly lower in VNR-treated mice (48%, n = 23) than in controls (84%, n = 19), as evaluated sixteen days after MB-49 orthotopic inoculation. Intravesical tumor volume was also significantly smaller in treated mice respect to controls (median [range]: 0.5 [0.4 to 61.8] mm.(3) versus 47.7 [4.2 to 179.7] mm.(3) respectively, p < 0.001 Kruskal-Wallis test). Median survival duration of the animals treated with VNR was 68 [21 to 68] days, and was significantly greater (p = 0.01, Kruskal-Wallis test) than that of untreated controls (18 [16 to 20] days). Conclusion: Intravesical VNR treatment demonstrated an evident antitumor effect against the TCC model assayed. The results obtained suggest a potential use of VNR as intravesical treatment for superficial TCC following transurethral bladder tumor resection to prevent recurrence or retard tumor growth.
引用
收藏
页码:912 / 915
页数:4
相关论文
共 19 条
[1]  
Bonfil RD, 1996, J UROLOGY, V156, P517
[2]  
BRODGEN J, 1995, ONCOL NURS FORUM, V22, P635
[3]  
FAIR WR, 1993, CANCER PRINCIPLES PR, P1052
[4]  
FLAMM J, 1990, EUR UROL, V17, P119
[5]  
Lamm D L, 1992, Semin Urol, V10, P39
[6]   APPARENT FAILURE OF CURRENT INTRAVESICAL CHEMOTHERAPY PROPHYLAXIS TO INFLUENCE THE LONG-TERM COURSE OF SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE BLADDER [J].
LAMM, DL ;
RIGGS, DR ;
TRAYNELIS, CL ;
NSEYO, UO .
JOURNAL OF UROLOGY, 1995, 153 (05) :1444-1450
[7]   Bladder cancer, 1996 [J].
Lamm, DL ;
Torti, FM .
CA-A CANCER JOURNAL FOR CLINICIANS, 1996, 46 (02) :93-112
[8]   RANDOMIZED STUDY OF VINORELBINE AND CISPLATIN VERSUS VINDESINE AND CISPLATIN VERSUS VINORELBINE ALONE IN ADVANCED NON-SMALL-CELL LUNG-CANCER - RESULTS OF A EUROPEAN MULTICENTER TRIAL INCLUDING 612 PATIENTS [J].
LECHEVALIER, T ;
BRISGAND, D ;
DOUILLARD, JY ;
PUJOL, JL ;
ALBEROLA, V ;
MONNIER, A ;
RIVIERE, A ;
LIANES, P ;
CHOMY, P ;
CIGOLARI, S ;
GOTTFRIED, M ;
RUFFIE, P ;
PANIZO, A ;
GASPARD, MH ;
RAVAIOLI, A ;
BESENVAL, M ;
BESSEN, F ;
MARTINEZ, A ;
BERTHAUD, P ;
TURSZ, T .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :360-367
[9]   SITE OF RECURRENCE OF NON-INFILTRATING BLADDER TUMORS [J].
PAGE, BH ;
LEVISON, VB ;
CURWEN, MP .
BRITISH JOURNAL OF UROLOGY, 1978, 50 (04) :237-242
[10]   INHIBITION OF IMPLANTATION OF MURINE BLADDER-TUMOR BY THIOTEPA IN CAUTERIZED BLADDER [J].
PAN, JS ;
SLOCUM, HK ;
RUSTUM, YM ;
GRECO, WR ;
GAETA, JF ;
HUBEN, RP .
JOURNAL OF UROLOGY, 1989, 142 (06) :1589-1593